[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1140 Introduced in House (IH)]

111th CONGRESS
  2d Session
H. RES. 1140

      Commending the progress made by anti-tuberculosis programs.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 4, 2010

Mr. Engel (for himself, Mr. Poe of Texas, Mr. Gene Green of Texas, Mr. 
 Payne, Ms. Lee of California, Ms. Baldwin, Mr. Doyle, Ms. Matsui, Mr. 
    Nadler of New York, Mrs. Maloney, Ms. Schakowsky, Mr. Smith of 
Washington, and Mr. Crowley) submitted the following resolution; which 
 was referred to the Committee on Foreign Affairs, and in addition to 
 the Committee on Energy and Commerce, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                               RESOLUTION


 
      Commending the progress made by anti-tuberculosis programs.

Whereas tuberculosis (hereafter in this preamble referred to as ``TB'') is the 
        second leading global infectious disease killer behind HIV/AIDS, 
        claiming 1,800,000 million lives each year;
Whereas the global TB pandemic and the spread of drug resistant TB present a 
        persistent public health threat to the United States;
Whereas according to 2009 data of the World Health Organization, 5 percent of 
        all new TB cases are drug resistant;
Whereas TB is the leading killer of people with HIV/AIDS;
Whereas TB is the third leading killer of adult women, and the stigma associated 
        with TB disproportionately affects women, causing them to delay seeking 
        care and interfering with treatment adherence;
Whereas the Institute of Medicine (IOM) found that the resurgence of TB between 
        1980 and 1992 was caused by cuts in TB control funding and the spread of 
        HIV/AIDS;
Whereas, although the numbers of TB cases in the United States continue to 
        decline, progress towards TB elimination has slowed, and it is a disease 
        that does not recognize borders;
Whereas New York City had to spend over $1,000,000,000 to control a multi-drug 
        resistant TB outbreak between 1989 and 1993;
Whereas an extensively drug resistant form of TB, known as XDR-TB (hereafter 
        referred to in this preamble as ``XDR-TB)''), is very difficult and 
        expensive to treat and has high and rapid fatality rates, especially 
        among HIV/AIDS patients;
Whereas the United States has had more than 83 cases of XDR-TB over the last 
        decade;
Whereas the Centers for Disease Control and Prevention estimated in 2009 that it 
        costs $483,000 to treat a single case of XDR-TB;
Whereas African-Americans are 8 times more likely to have TB than Caucasians, 
        and significant disparities exist among other United States minorities, 
        including Native Americans, Asian-Americans, and Hispanic Americans;
Whereas the United States public health system has the expertise to eliminate 
        TB, but many State TB programs have been left seriously under-resourced 
        due to budget cuts at a time when TB cases are growing more complex to 
        diagnose and treat;
Whereas, although drugs, diagnostics and vaccines for TB exist, these 
        technologies are antiquated and are increasingly inadequate for 
        controlling the global epidemic;
Whereas the most commonly used TB diagnostic in the world, sputum microscopy, is 
        more than 100 years old and lacks sensitivity to detect TB in most HIV/
        AIDS patients and in children;
Whereas current tests to detect drug resistance take at least 1 month to 
        complete and faster drug susceptibility tests must be developed to stop 
        the spread of drug resistant TB;
Whereas the TB vaccine, BCG, provides some protection to children, but has 
        little or no efficacy in preventing pulmonary TB in adults;
Whereas there is also a critical need for new TB drugs that can safely be taken 
        concurrently with antiretroviral therapy for HIV;
Whereas the Global Health Initiative commits to reducing TB prevalence by 50 
        percent through 2015;
Whereas enactment of the Lantos-Hyde Global Leadership Against HIV/AIDS, TB and 
        Malaria Act and the Comprehensive TB Elimination Act provide an historic 
        United States commitment to the global eradication of TB, including to 
        the successful treatment of 4,500,000 new TB patients and 90,000 new 
        multi-drug resistant (MDR) TB cases by 2013, while providing additional 
        treatment through coordinated multilateral efforts;
Whereas the United States Agency for International Development provides 
        financial and technical assistance to nearly 40 highly burdened TB 
        countries and supports the development of new diagnostic and treatment 
        tools, and is authorized to support research to develop new vaccines to 
        combat TB;
Whereas the Centers for Disease Control and Prevention, working in partnership 
        with States and territories of the United States, directs the national 
        TB elimination program and essential national TB surveillance, technical 
        assistance, prevention activities and supports the development of new 
        diagnostic, treatment and prevention tools to combat TB;
Whereas the National Institutes of Health, through its many institutes and 
        centers, plays the leading role in basic and clinical research into the 
        identification, treatment and prevention of TB; and
Whereas the Global Fund to Fight AIDS, Tuberculosis and Malaria provides 63 
        percent of all international financing for TB programs worldwide and 
        finances proposals worth $3,200,000,000 in 112 countries, and TB 
        treatment for 6,000,000 and HIV/TB services for 1,800,000, and in many 
        countries in which the Global Fund supports programs, TB prevalence is 
        declining, as are TB mortality rates: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) commends the progress made by anti-tuberculosis 
        programs, including the U.S. Agency for International 
        Development, the Centers for Disease Control and Prevention and 
        the Global Fund to Fight AIDS, Tuberculosis and Malaria; and
            (2) reaffirms its commitment to global tuberculosis control 
        made through the Lantos-Hyde U.S. Leadership Against HIV/AIDS, 
        Tuberculosis and Malaria Act of 2008.
                                 <all>